Great thread here from @dmgorenstein on the some of the key facts from our story about Truvada and PrEP today. We talk about a lot more in the episode on online which you should def check out: tradeoffs.org/2021/04/22/pre…
I wanted to share a few of my own big picture takeaways... 🧵
The Truvada case is fascinating to me because it includes so many classic drug pricing issues (patents, pay-for-delay, product hopping), but it also has so many unique wrinkles that make it that much harder to draw simple conclusions about the impact of high prices on use.
